Clinical Trials Logo

Filter by:
NCT ID: NCT03528928 Active, not recruiting - Clinical trials for Pelvic Floor Disorders

Viewing Surface Electrical Stimulation on Pelvic Floor With Ultrasound

Start date: April 17, 2018
Phase: N/A
Study type: Interventional

Subjects will place a surface electrode on their perineal area after a bladder-filling protocol. Transabdominal ultrasound will image the base of the bladder at rest, voluntary pelvic floor contraction, with the surface electrical stimulation and with a combined pelvic floor contraction and electrical stimulation active.

NCT ID: NCT04312399 Active, not recruiting - Alzheimer Disease Clinical Trials

Hormone Replacement Trial Against ALzheimers' Disease

HARALD
Start date: April 17, 2018
Phase: N/A
Study type: Interventional

The influence of postmenopausal hormone treatment on dementia is not clear. Dysfunctions in the metabolism of amyloid in the disease of Alzheimer result in an elevated presence of degradation products in cerebrospinal fluid. The degradation products in blood will be analysed during the trial, to get better insight in menopause and the start of hormonal therapy. Postmenopausal women with and without history of breast cancer will be recruited for the trial.

NCT ID: NCT04503356 Active, not recruiting - Cataract Clinical Trials

OMNI in Open-angle Glaucoma Treatment

Start date: April 17, 2018
Phase: N/A
Study type: Interventional

This single-center, prospective study will assess safety and effectiveness of 360 degree viscodilation followed by up to 360 degree trabeculotomy used in patients with early or moderate open-angle glaucoma in a real-world setting either as a standalone procedure in pseudophakic patients (or phakic) or combined with phacoemulsification cataract procedures. Medication usage, IOP and secondary surgical procedures necessary for IOP control will be analyzed during the follow-up period.

NCT ID: NCT05582447 Active, not recruiting - Cholestasis Clinical Trials

Osmotic Fragility in Red Blood Cells of Pediatric Patients With Cholestatic Liver Disease

Start date: April 17, 2018
Phase:
Study type: Observational

Objective: The investigators propose to perform ektacytometry on 20 pediatric patients over age one with cholestatic liver diseases and a direct bilirubin level of greater than 2 gm/dl. The most common diagnoses will be extrahepatic biliary atresia, progressive familial intrahepatic cholestasis, Alagille syndrome, autoimmune hepatitis, primary sclerosing cholangitis, and parenteral nutrition-associated cholestasis. The investigators will correlate the osmotic fragility and deformability with direct bilirubin levels, serum cholesterol levels, serum bile acid levels, and vitamin E levels. Design/Methods: This pilot study will be a single center, prospective cross-sectional investigation of red blood cell ektacytometry in pediatric patients with extrahepatic cholestasis who are followed at Cincinnati Children's Hospital Medical Center. The study will include all participants with cholestasis regardless of the etiology in order to maximize the number of participants. While the population will be heterogeneous, the investigators will stratify participants according to diagnosis, recognizing that only a few participants may fall into each diagnostic category. Ektacytometry will be the method utilized to measure osmotic fragility and deformability of the RBC membrane. The ektacytometry of red cells from cholestatic patients will be compared to that of red cells obtained from contemporaneous age-matched controls recruited among patients without liver disease or red cell membrane defects undergoing blood sampling for evaluation of other entities including but not confined to functional abdominal pain.

NCT ID: NCT03721952 Active, not recruiting - Clinical trials for Pulmonary Disease, Chronic Obstructive

Facilitating Communication Study

FCS2
Start date: April 17, 2019
Phase: N/A
Study type: Interventional

This study is a randomized clinical trial of an intervention to improve outcomes for patients and their family by using ICU nurse facilitators to support, model, and teach communication strategies that enable patients and their families to secure care in line with patients' goals of care over an illness trajectory, beginning in the ICU and continuing to care in the community.

NCT ID: NCT03785964 Active, not recruiting - Desmoid Tumor Clinical Trials

Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)

DeFi
Start date: April 17, 2019
Phase: Phase 3
Study type: Interventional

This study evaluates nirogacestat (PF-03084014) in the treatment of desmoid tumor/aggressive fibromatosis (DT/AF). In the double-blind phase, half of the participants will receive nirogacestat while the other half will receive placebo. Once participants are eligible to roll into the open-label phase, they will receive nirogacestat.

NCT ID: NCT03792516 Active, not recruiting - Vulvar Diseases Clinical Trials

Artesunate Ointment for the Treatment of High Grade Vulvar Intraepithelial Neoplasia (HSIL VIN2/3)

ART-VIN
Start date: April 17, 2019
Phase: Phase 1
Study type: Interventional

This is a Phase I, proof-of-concept treatment study to evaluate the safety, tolerability and feasibility of topical artesunate ointment to treat high grade vulvar intraepithelial neoplasia (HSIL VIN2/3).

NCT ID: NCT03806608 Active, not recruiting - Partial Edentulism Clinical Trials

Evaluation of MBL Around Implants Placed in Crestal or Subcrestal Positions: a RCT

Start date: April 17, 2019
Phase: N/A
Study type: Interventional

The objective of this randomized controlled trial is to evaluate changes in marginal bone levels and soft tissue dimensions around implants placed with the IAI at different positions in relation to the alveolar crest

NCT ID: NCT03829020 Active, not recruiting - Clinical trials for Recurrent Plasma Cell Myeloma

Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple Myeloma

Start date: April 17, 2019
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of metformin and nelfinavir in combination with bortezomib in treating patients with multiple myeloma that has come back or does not respond to treatment. Metformin may stop the growth of tumor cells by disrupting the energy source within multiple myeloma cells. Nelfinavir and bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving metformin, nelfinavir, and bortezomib may work better in treating patients with multiple myeloma.

NCT ID: NCT03852719 Active, not recruiting - Clinical trials for Chronic Hepatitis Delta

Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (CHD)

Start date: April 17, 2019
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate the efficacy of bulevirtide for treatment of chronic hepatitis delta (CHD) in comparison to delayed treatment.